Contract research organisation (CRO) Worldwide Clinical Trials (Worldwide) has introduced a new AI-driven tool for improving optimisation of studies.
This service aims to “segment” subject populations, detecting the potential ones exhibiting positive study outcomes, which results in significant reductions in trial subject numbers, timelines, and expenses for trial sponsors.
The tool leverages AI algorithms that are NetraMark-powered to process complex data sets such as genomics, clinical scales, and transcriptomics.
This analysis is crucial for detecting factors that can “optimise” endpoint results.
By focusing on the subject variables, the company offers sponsors transparent, rapid, clinically grounded insights.
These insights are instrumental in refining the design of the trial, minimising variability, and enhancing response prediction accuracy.
The technology is particularly adept at backing enrichment strategies, which involve decreasing variability, enhancing prognosis, and optimising response prediction by concentrating on patients more likely to benefit from the drug treatment.
Worldwide Clinical Trials chief operating officer Dave Bowser said: “The introduction of this new service for our customers marks a significant advancement in our commitment to optimise clinical trials.
“This service enhances trial efficiency and delivers regulatory-aligned insights from even the most complex datasets – leading to more successful trials while saving our customers valuable time and resources.”
With this new tool, Worldwide aims to enable sponsors to bring treatments to market.
Worldwide collaborates with pharma and biotechnology companies to generate “customised” solutions that support the development of new medications.
Their services range from bioanalytical laboratory services to Phase I-IV trials, as well as post-approval and real-world evidence trials.
In a strategic move to accelerate the discovery of treatments for rare diseases, Worldwide entered a collaboration with Every Cure in May 2023.
